01 1Cipla
01 1REVEFENACIN
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2022-05-20
Pay. Date : 2022-05-13
DMF Number : 36737
Submission : 2022-05-06
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is REVEFENACIN, with a corresponding US DMF Number 36737.
Remarkably, this DMF maintains an Active status since its submission on May 06, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 20, 2022, and payment made on May 13, 2022, indicating their dedication to facilitating drug approvals, Categorized as Type II
